# Ethical Decisions in Transplantation

P.-A. Clavien

Department of Surgery University Hospital Zurich

- Determination of death
- > Allocation of organs
- Living donation



- > Selection of patients for transplantation
- > Drug abuse / compliance
- > Retransplantation

#### **Determination of brain death**

Ethic of donors


- > Cerebral and brain stem functions must be absent
- The cause of the lack of brain functioning must be determined to be irreversible



The absence of all brain function must have persisted during a period of observation

### Definition of biological life

Alexis Carrel ",the secret of life 1912"



### The secret of life, A. Carrel

'If it were possible immediately after death to transplant the tissues and organs. . . into other organisms of identical character, no elemental (meaning no irreversible) death would occur, and all the

constituent part of the body


would continue to live'



Ethic of recipients?


organ transplantation after cardiac death (DCD)

### Organ transplantation



### **Outcome after Transplantation**






Time since Tpx (in years)

Swiss Cohort study

### **Survival after Transplantation**






Time since Tpx (in years)


### Problem

limited number of organs



High number of candidates






Indication?


#### **Kidney allocation**



#### **Liver allocation**









Tim Pruitt, Waiting for liver transplantation. The Titanic effect. Liver Transplanation 2005

### Organ transplantation



#### Criteria for donation

- No transmission of tumor of untreatable infection
- **Estimated** sufficient post transplant organ function

Donor risk index Graft appearance

Prediction of graft function?

#### **Criteria for transplant candidates**

- Compliance
- Residence in Switzerland

Prediction of recipient outcome? Post transplant survival after liver transplantation more than 50 % after 5 year (BAG)

### **Current challenge**

#### Donor

- High donor age
- Race
- Extended cold ischemia - Warm ischemia
- Graft steatosis
- Infectious disease - Cause of death

#### Marginal graft







#### Recipient

- End stage liver disease

- Hepatitis C

- Liver Cancer

- High recipient age

- Obesity

- Previous transplant - Portal vein thrombosis

#### **MELD > 35**



### **Example tumor size**

**25 y**, suspected 12 x 6 cm diffuse HCC, Hep B, Child A




Liver transplant 2011 (donor age 88 y)

Histology post transplant: 4 cm HCC


2014: tumor free, back to full work

#### **Example tumor size**

**25 y**, suspected 12 x 6 cm diffuse HCC, Hep B, Child A



**43 y**, 7 x 6 cm central HCC, Hep C, Liver cirrhosis Child B



Liver transplant 2011 (donor age 88 y)

Histology post transplant: 4 cm HCC

Liver transplant 2005, **Histology post transplant: 4 cm HCC** 

2014: tumor free, full work

2014 : tumor free, Hep c free, full work

#### **Liver Cancer**


Criteria	Features	5-year Survival
Milan <sup>68</sup>	Single tumor ≤5cm Up to 3 tumors each ≤3cm	>80%
UCSF <sup>73</sup>	Single tumor ≤ 6.5cm, or Two tumors ≤ 4.5cm or Total diameter ≤ 8cm	75%
Hangzhou <sup>80</sup>	Tumor < 8cm in total or Tumor ≥ 8 and AFP ≤ 400ng/ml and well differentiated	72%
Toronto <sup>71</sup>	Any tumor size or number and No macrovascular invasion and No extra-hepatic disease and Well or moderate differentiated (when beyond Milan)	70%
Up to Seven <sup>69,78</sup>	Largest tumor size ≤ 7cm or Tumor number ≤ 7	71%
Asan Medical Center <sup>82</sup>	Largest tumor size ≤ 5cm or Tumor number ≤ 6cm with macrovascular invasion	82%
Kyoto <sup>81</sup>	Largest tumor diameter ≤ 5cm Tumor number ≤ 10cm	87%
Tokyo University <sup>79</sup>	Largest tumor diameter ≤ 5cm Tumor number ≤ 10cm  Largest tumor size < 5cm Tumor number ≤ 5cm Tumor number ≤ 5cm	75%
	Milaria	

## Ethical dilemma



### Introduction of "MELD" Policy

"sickest first"



### Example too sick?

**63 J**, BMI 17.9, MELD 32, hemofilter, ICU



year after


Transplantation

Liver transplant 2008

6 years after

Transplantation

### Survival benefit?



doi: 10.1111/j.1600-6143.2009.02571.x


### Survival Benefit-Based Deceased-Donor Liver Allocation

D. E. Schaubel<sup>a,b,\*</sup>, M. K. Guidinger<sup>b,c</sup>, S. W. Biggins<sup>d</sup>, J. D. Kalbfleisch<sup>a,b</sup>,


E. A. Pomfret<sup>e</sup>, P. Sharma<sup>f</sup> and R. M. Merion<sup>b, g</sup>

Organ Procurement and Transplantation Network (OPTN), Scientific Registry of Transplant Recipients (SRTR), waiting list


Schaubel et al.




### New calculation of categorized <u>key risk factors</u> Adult UNOS population, n=37255



### Threshold of increasing mortality after OLT



#### **Current policy**



### Individual vs collective benefit

The goal of liver transplantation is to maximize the benefits that can be provided to patients through the most judicious and fair use of the limited supply of donor organs. In practice, the problem of the donor organ shortage influences the indications for liver transplantation. In this context, it is necessary to make choices that favor collective benefits rather than individual benefits for patients while we attempt to

# Triage?



### Example acute liver failure during pregnancy

Acute Hepatitis B 21 weeks of pregnancy, MELD 30




14 cases world wide, most with fatal outcome most with fetus for the fetus




- Liver transplant 2012 with super urgent listing (grant offer from France)
- Sectio 3 months later with healthy child


#### Example iatrogenic injury after lap. cholecystectomy




**80 y,** benign disease Send from another hospital after <u>iatrogenic</u> injury

Complete transsection of the bilary bifurcation & the common hepatic artery





G. B. Shaw 1906 The Doctor's dilemma



«I have had to consider not only whether the man could be saved but whether he was worth saving.

There were fifty cases to choose from and forty had to be condemned to death»

### Steve Jobs Liver Transplant – Is That Ethical?

posted by hfields



UPDATE: Interesting NY Times article asking some of the same questions as my original post about Steve Jobs' liver transplant. Check the NY Times piece out! Because of this article, and because of the many comments I received on my own, I'm putting up an updated version of my prior post today (below), but with some changes to reflect better information. Unfortunately, by putting up this new version, the old one was deleted, so some of the comments on it may no longer apply. Anyhow, enough disclaimers!

### **Example chronic drug abuse & tumor**

- **45** y, Hep C
- Chronic <u>drug abuse from 1998 -2000</u>, currently Methadon program
- Suspicion on hilar cholangiocarcinoma (bile duct cancer)
- No disease outside the liver


Radio-Chemotherapy after staging (Mayo protocol)

### LEBEN


Tages Anzeiger	WIRTSCHAFT	BÖRSE SPORT	KULTUR	PANORAMA I
ZÜRICH SCHWEIZ  Gesellschaft Reisen	AUSLAND WIRTSCHAFT Style Wein Wohnen Ma	mablog Sweet Hom	e Ollius	

### **Recht auf Rettung**

Von Mario Stäuble. Aktualisiert am 05.03.2012 14 Kommentare Menga V. war drogensüchtig, leidet an Depressionen und hat zwei Suizidversuche hinter sich. Nun die Diagnose: Krebs, Sie braucht eine neue Leber, aber Spenderorgane sind knapp. Soll sie eine erhalten?







Liver transpant 2011 with poor arteryrequiring complex reconstruction (liver graft rejected by all other centers))

### Example sick & drug abuse

- 34 y, acute alcoholic steatohepatitis, lab MELD 38
   Intubated, on hemofilter, 20 y Noradrenalin
- On list 09/2013 after repeated discussions with parents, psychologists, hepatologists, Anaesthesists, Ethicists
- Liver transplant 10/2013,Donor age 70 y + graft fibrosis

2014 : full recovery, back to work

#### ORIGINAL ARTICLE

#### Early Liver Transplantation for Severe Alcoholic Hepatitis

Philippe Mathurin, M.D., Ph.D., Christophe Moreno, M.D., Ph.D.,
Didier Samuel, M.D., Ph.D., Jérôme Dumortier, M.D., Ph.D., Julia Salleron, M.S.,
François Durand, M.D., Ph.D., Hélène Castel, M.D., Alain Duhamel, M.D., Ph.D.,
Georges-Philippe Pageaux, M.D., Ph.D., Vincent Leroy, M.D., Ph.D.,
Sébastien Dharancy, M.D., Ph.D., Alexandre Louvet, M.D., Ph.D.,
Emmanuel Boleslawski, M.D., Ph.D., Valerio Lucidi, M.D., Thierry Gustot, M.D., h.a.,
Claire Francoz, M.D., Christian Letoublon, M.D., Denis Casteing SAID,
Jacques Belghiti, M.D., Vincent Donckie and L., Cold.,
François-René Pruvot, M.D., and Jean Shalle Duckos-Vallée, M.D., Ph.D.






# Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy

Vincent Donckier<sup>1,\*</sup>, Valerio Lucidi<sup>1</sup>, Thierry Gustot<sup>2</sup>, Christophe Moreno<sup>2</sup>

<sup>1</sup>Department of Abdominal Surgery, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; <sup>2</sup>Department of Gastroenterology, Liver Transplant Unit, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

 Severe alcoholic hepatitis refers to a life-threatening syndrome of liver failure and systemic inflammation arising in persons who have been consuming excess amounts of alcohol. In this condition, the absence of response to medical therapy is associated with extremely high early mortality

# Estimates of Survival among 26 study patients and randomly selected matched controls



#### **Example retransplant**

- 51 y, Hep C
- First liver transplant 2004
- Recurrent Hep C cirrhosis, <u>second</u> liver transplant 2009

Chronic rejection and severe graft injury, persisting Hep C

Third liver transplant 2011

Justified?

Normal graft function, Hep C treatment with new nucleotide polymerase inhibitor sofosbuvir

#### Example ECD/DCD organ, rejected by others

71 y, Liver fibrosis, HCC wedge resection 2008 Recurrent HCC, 6 x TACE Right Hepatectomy 2010


Recurrent HCC near the v. cava

Liver transplant 2013

25.1 mm 24.5 mm

Donor offer rejected by all other centers:

Suizid, ALT 1016 U/I, Quick 32



## Example ECD/DCD organ, rejected by others

Ultrasound report donor:

Regelrechte Darstellung der Leber ohne Nachweis fokaler Läsionen.





- 8 cm cystic lesion in left lobe
- Resection on backtable

Recipient with HCC, expected waiting time > 1 y



## **Ethics in Living donor transplant**

Ethical acceptable

Ethical inacceptable

Adult donating Pediatric recipient

Cancer outside the liver

Expected donor mortality risk > 0.5 %

## Double equipoise






R: 75yr man, Liver cancer *above Milan* 



D: 20 yr loving grand child

# Should We Use Living Donor Grafts for Patients With Hepatocellular Carcinoma? Ethical Considerations

Elizabeth A. Pomfret, 1 J. Peter A. Lodge, 2 Federico G. Villamil, 3 and Mark Siegler 4



**Recipient benefit** 

Clavien PA et al. Liver transplanatation for liver cancer. Lancet Oncol 2011


## Double equipoise



R: mother of 3 children

Liver cancer above UCSF


D: father



**Recipient benefit** 

# Example Living donor liver transplantation + heart resection

- > 22 year old, female patient, <u>unresectable</u> echinococcus alveolaris in the liver
- Incidence of echinococcus in Switzerland: 10-20 cases/y, 90 % mortality (untreated)



Infiltration of suprahepatic vena cava and right atrium



### Regular treatment options?

None

Liver transplantation with resection of right atrium and vena cava

But.....no perspective for an organ offer



**Evaluation: Living donor liver transplantation** 

Never done before, mortality?


#### **Donor Evaluation**

Sister, 26 years

1: Segment (V, VI, VII, VIII): 624 cm3

2: Segment IV: 101cm3

**3:** Segment I, II, III: 223 cm3



Operation in parallel:

**Team 1:** Donor operation (resection of right hemiliver)


**Team 2:** Recipient operation (resection liver including right atrium, cava vein and implantation of right hemiliver from donor

+

Team 3: In cooperation with Heart/Vascular Surgeon (Prof. Lachat)

#### **Living Donor Liver transplantation**

Donor operation




## Operation


**Team 1:** Donor operation

**Team 2:** Recipient operation

#### Resection








Replacement of right atrium


Replacement of diaphragm


Replacement of liver

Replacement of vena cava



#### Diseased liver of recipient with echinococcus





- Complete recovery of the patient (1.5 year follow-up)
- No immunosuppression
- HLA-Identity of donor and recipient





















# How to define thresholds? How to move forward?



## Marginal Organs










Dutkowki, Clavien, et al. Gastroenerology 2014

Hypothermic oxygenated machine perfusion, Case 1-20:



#### Assessment of injury before implantation?

AST/ALT release during machine liver perfusion



## Ethical decisions in transplantation

# Future interdisciplinary research needed ...

- Indications for transplant
- tumor limits?
  recurrent chronic drug abuse?

Allocation principles

...to the sickest recipient?

Retransplantation for early graft failure

second chance?

Donation after cardiac death

donor treatment? graft injury limits?

Living donor transplantation

donor risk? recipient benefit?

Acute liver failure after suizide/drug abuse

justified?

# big picture



HSM including
Transplantation should be permitted only in centers performing credible research



